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Introduction
Introduction of hybrid positron emission tomography 
and computerized tomography (PET/CT) has allowed 
concurrent functional and morphological imaging with 
better sensitivity, specificity and diagnostic accuracy (Von 
Schulthess et al., 2006). For these reasons PET/CT has 
become an important component of management paradigm 
in oncology as it helps in diagnosis, staging, restaging, 
response evaluation and prognostication (Zaman et al., 
2014). CT component in hybrid PET/CT is used for 
attenuation correction, anatomical correlation without or 
with diagnostic quality imaging. 
In recent era, due to arrival of very effective new 
therapies, overall survival of many cancers has improved 
especially lymphoma and childhood cancers (Milana 
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Abstract
 Background: Fluorodeoxyglucose (18FDG) PET/CT imaging has become an important component of the 
management paradigm in oncology. However, the significant imparted radiation exposure is a matter of growing 
concern especially in younger populations who have better odds of survival. The aim of this study was to estimate 
the effective dose received by patients having whole body 18F-FDG PET/CT scanning as per recent dose reducing 
guidelines at a tertiary care hospital. Materials and Methods: This prospective study covered 63 patients with 
different cancers who were referred for PET/CT study for various indications. Patients were prepared as per 
departmental protocol and 18FDG was injected at 3 MBq/Kg and a low dose, non-enhanced CT protocol (LD-
NECT) was used. Diagnostic CT studies of specific regions were subsequently performed if required. Effective 
dose imparted by 18FDG (internal exposure) was calculated by using multiplying injected dose in MBq with 
coefficient 1.9×10-2 mSv/MBq according to ICRP publication 106. Effective dose imparted by CT was calculated 
by multiplying DLP (mGy.cm) with ICRP conversion coefficient “k” 0.015 [mSv / (mG. cm)]. Results: Mean age 
of patients was 49 ±18 years with a male to female ratio of 35:28 (56%:44%). Median dose of 18FDG given was 
194 MBq (range: 139-293). Median CTDIvol was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70 - 576.70). 
Estimated median effective dose imparted by 18FDG was 3.69 mSv (range: 2.85-5.57). Similarly the estimated 
median effective dose by low dose (non-diagnostic) CT examination was 4.93 mSv (range: 2.14 -10.49). Median 
total effective dose by whole body 18FDG PET plus low dose non-diagnostic CT study was 8.85 mSv (range: 
5.56-13.00). Conclusions: We conclude that the median effective dose from a whole body 18FDG PET/CT in our 
patients was significantly low. We suggest adhering to recently published dose reducing strategies, use of ToF 
scanner with CT dose reducing option to achieve the lower if not the lowest effective dose. This would certainly 
reduce the risk of second primary malignancy in younger patients with higher odds of cure from first primary 
cancer. 
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et al., 2015; Uslu et al., 2015). These patients on an 
average do have at least 2-3 PET/CT scans during their 
management and in view of better survival especially 
in younger population radiation dose incurred by 
these procedures is a major concern. CT component 
contributes more than 60% of effective dose to patients 
and increase the life time attributable risk (LAR) for 
second primary malignancy (Jallow et al., 2016). To 
address this issue, recent guidelines have recommended 
use of low dose non-contrast enhanced CT for attenuation 
correction and anatomical mapping and smaller doses 
of fluorodeoxyglucose (18FDG) (Boellaard et al., 2015).
At the moment in Pakistan, there are four FDG 
based PET/CT facilities catering a population of more 
200 million. Our facility being the youngest and the 
only accredited tertiary healthcare PET/CT facility by 
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Joint Commission is strictly following these recent dose 
minimizing recommendations. To the best of our search, 
there is no local data regarding the radiation dose to 
patients who have FDG based PET/CT as per recently 
published protocols (Graham et al., 2015).
The objective of this study was to estimate the effective 
dose received by patients having whole body 18FDG PET/
CT scanning as per recent dose reducing guidelines at a 
tertiary care hospital.
Materials and Methods
This was a prospective study performed at the PET/
CT facility of Aga Khan University Hospital, Karachi, 
Pakistan from March-April 2016. As per departmental 
protocol, patients were fasted for at least 4 hours but 
encouraged maintaining hydration with plain water. 
Diluted oral gastrografin (10 cc in liter water) was given to 
patient to drink at least 1 hour prior to radiotracer injection. 
Fasting blood glucose <200 mg/dl was mandatory and 
test were rescheduled if it ≥200 mg/dl. Patients were 
positioned on bed/recliner in uptake room and 18FDG 
was injected intravenously (3 MBq/kg) followed by flush 
with 10 cc of normal saline. During uptake period (50-75 
minute) patients were encouraged to take 500 ml of plain 
water with gastrografin and were asked to void bladder 5 
minutes prior the PET/CT imaging.
PET/CT images were acquired using Toshiba 
Celesteoin with 16 slice CT (Toshiba Med Corp, Japan). 
The PET scanner has lutetium oxyorthosilicate (LSO) 
crystal detectors with a time of flight (ToF) resolution time 
<450 picoseconds. A scout view was acquired to plan the 
study, followed by a non-contrast enhanced CT (NECT) 
protocol in cranio-caudal direction for the purpose 
of anatomical localization and attenuation correction 
(Tube Potential: 120 kVp; Tube Current: upto 120 mAs; 
Rotation Time 0.58 sec/rotation; Slice Thickness: 1mm). 
Subsequently a three dimensional PET scan was acquired 
at 3 min/bed position in a caudo-cranial direction. 
The effective dose imparted by 18FDG (internal 
exposure) was calculated by using coefficient 
1.9×10-2milliSievert/Mega Becquerel(mSv/MBq) 
according to ICRP publication 106 (ICRP 2008).To 
estimate the effective dose from whole body CT scan 
(external exposure), volume CT Dose Index (CTDIvol 
in milliGray [mGy]) and Dose length Product (mGy. 
cm) was directly obtained from the display screen of CT 
workstation. Effective dose was calculated by multiplying 
DLP (mGy.cm) with ICRP conversion coefficient “k” 
0.015 [mSv / (mG. cm)] (Christner et al., 2010).
Results 
Total 63 patients were included in this study who 
were referred for 18FDG PET/CT examinations for 
their oncological workup (staging 40%, restaging 11%, 
response evaluation 30%, Follow-up 17%; Surveillance 
02%). Out of these 63 patients, 20 (32%) had lymphoma, 
09 (14%) had gastrointestinal, 06 (10%) had breast, 5 (8%) 
ovarian, 5 (8%) had carcinoma of unknown primary, 4 
(6%) each for kidney/urinary bladder and mouth and 10 
(16%) miscellaneous cancers. Nineteen (30%) patients 
have had at least 1 PET/CT examination in past. Mean age 
Table 2. Effective Doses (mSv) Imparted by 18FDG, CT and Total by a PET/CT Study
Effective Dose by 18FDG 
Median (mSv) (Range) 
(1.9×10-2 mSv/MBq x MBq)





3.69 (2.85-5.57) 4.93 (2.14-10.49) 8.85 (5.56-13.00)
* k = 0.015 [mSv / (mG. cm)] (Christner et al., 2010)
Figure 1. Maximum Intensity Projection (MIP) Whole 
Body PET Images Acquired with Lowest and Highest 
Injected Doses of 18FDG
	  
Table 1. Study Demographics
Variables N=63
Mean Age ± SD 49 ± 18
Male: Female 35:28 (56:44%)
BMI (Kg/m2) 24.42 ± 4.22
Previous PET-CT study 19 (30%)
Median (range) dose of FDG (MBq) 194 (139-293)
Median (range) Mean Uptake Time 70 (55-97)
Mean FBS ± SD (mg/dl) 111 ± 26
Median (range) CTDIvol 3.25 (2.4-6.2)
Median (range) DLP 334.95 
(246.70-576.70)
Mean ± SD Hepatic SUVmean 1.71 ± 0.44
Indication
Follow-up 11 (17%)




Positive: Negative 47:16 (75:25%)
SD=standard deviation; BMI=Body mass index; FDG=Fluorodeoxy 
Glucose; FBS=Fasting Blood Sugar; CTDI=CT dose Index; DLP= Dose 
Length Product; FU= Follow-up; RE= Response Evaluation; RS= Re-
Staging; SG= Staging; SV= Surveillance
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of patients was 49 ±18 years with a male to female ratio of 
35:28 (56%:44%). Mean body mass index (BMI) of cohort 
was 24.42 ± 4.22 Kg/m2. Mean fasting blood glucose 
level was 111 ± 26 mg/dl. Median dose of 18FDG given 
was 194 MBq (range: 139-293) and median uptake time 
was 70 minute (range: 55-97). Mean hepatic standardized 
uptake value (Hep SUVmean was 1.71 ± 0.44). PET/CT 
examination was positive for 18FDG avid lesion (s) in 47 
(75%) and negative in 15 (25%) cases. Median CTDIvol 
was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70 
- 576.70) (Table 1).
Estimated median effective dose imparted by 18FDG 
was 3.69 mSv (range: 2.85-5.57). Similarly the estimated 
median effective dose by low dose (non-diagnostic) CT 
examination was 4.93 mSv (range: 2.14 -10.49). Median 
total effective dose by whole body 18FDG PET plus low 
dose non-diagnostic CT study was 8.85 mSv (range: 5.56-
13.00) (Table 2). 
Discussion
AIn recent days 18FDG based PET/CT imaging has 
become an essential component of management paradigm 
of many cancers (Ghotbi et al., 2007). A whole-body PET/
CT scanning is accompanied by substantial radiation dose 
to the patients. We must be cognizant of importance of 
potential risk from radiation exposure (i.e. second primary 
malignancy) which must be gauged and understood so 
that risk-benefit ratios can be assessed. This is particularly 
important for younger population with better probability 
of post-treatment survival. To address this issue, various 
societies have issued appropriate use criteria, designed 
imaging protocol and stressed upon using time of flight 
(ToF) scanners which have better signal to noise ratio even 
with lower injected dose of radiotracer. In our study, low 
dose CT contributed about 60% of total effective dose 
to the patients. This is slightly higher than a recently 
published study in which CT contribution to total dose 
was 54% as they have used higher injected dose of 18FDG 
than our protocol (194 MBq vs 341 MBq) (Mahmud et al., 
2014). However, percentage contribution in our study was 
significantly lower than another published study which 
has a reported contribution of about 80% but they have 
used a diagnostic rather than low dose CT scan (Huang 
et al., 2009).
Median effective dose from PET study in this study 
was 3.69 mSv for median injected 18FDG dose of 194 
MBq. This dose is in accordance with recent European 
Association of Nuclear Medicine (EANM) guidelines 
(Boellaard et al., 2015). Effective dose delivered by 18FDG 
in this study (i.e. 3.69 mSv) is significantly lower than 
published studies (6.30 and 6.23 mSv) (Huang et al., 2009; 
Mahmud et al., 2014). The most plausible explanations 
for this disparity are (1) not following dose reducing 
strategy; (2) well known concept of lower image quality 
with lower radiotracer dose. However, it is now a well-
established fact that shorter timing resolution of scanner 
with ToF option ensures better signal to noise ratio, better 
image quality, reduced imaging time and improve lesion 
detectability (Surti 2015). Since the timing resolution of 
our ToF scanner was<450 picoseconds, the image quality 
was good even with low doses of 18FDG (Figure1). This 
technical fact seeks attention of those nuclear medicine 
users who are using higher doses of 18FDG despite of 
having PET scanners with ToF option. Median effective 
dose delivered by low dose non-enhanced CT in this study 
was 4.93 mSv and this is significantly lower than effective 
dose of 7.50 mSv reported in the published data (Mahmud 
2014). The sentinel reason for this low CT effective dose 
is availability of Adaptive Iterative Dose Reduction-3D 
(AIDR-3D) technology in our CT scanner. These results 
endorse the effectiveness of dose reducing strategies 
recommended by current EANM guidelines which 
encourage non-diagnostic CT as routine and discourage 
the use of diagnostic quality CT with intravenous and oral 
contrasts (Boellaard et al., 2015). We acquired diagnostic 
CT study for a particular region of the body after acquiring 
whole body PET/CT with a low-dose CT scan protocol 
which is also regarded as a preferable option by recent 
guidelines (Boellaard et al., 2015).
Median total effective dose imparted by PET/CT scan 
in this study was 8.85 mSv. To the best of our search this 
is the lowest reported dose imparted to patient by a single 
PET/CT study. The lowest reported median effective 
dose is 13.8 mSv using a low dose non-enhanced CT 
(Mahmud 2014). While median effective doses reported 
in other studies are 25 mSv (Brix et al., 2005) and 24.8 
mSv (Chawla et al., 2010). 
So this study draws our attention towards an important 
fact that the effective dose from a whole body PET/CT 
scan at our Institute is significantly lower if not lowest 
(although we could not find any published data matching 
this low dose). As mentioned above, reasons for this 
significantly lower (if not lowest) are adherence to the dose 
reducing strategies mentioned in recent guidelines and use 
of a scanner with the lowest ToF and CT dose reducing 
module. We are confident that reducing the effective dose 
of a whole body PET/CT study would reduce the risk of 
second primary malignancy in our younger patients who 
have better odds of cure from their primary cancers like 
lymphomas (Milana et al., 2015). Therefore, it is justifiable 
to note that the radiation dose resulting from the PET/CT 
scan has to be tailored to the needs of the study and the 
impact of doing so should outweigh the radiation effect.
This study has some limitations and primary one is 
smaller sample size. We are cognizant of the fact that 
larger sample size would enhance the statistical strength 
but these preliminary results from available data pave 
the path for a larger prospective study. Second limitation 
is use of simple strategies for effective dose calculation. 
However, the coefficients factors used in this study have 
been derived from well designed and validated studies. 
Third limitation is that we did not calculate lifetime 
attributable risk for cancer and would like to use in other 
prospective study.
We conclude that the median effective dose from 
a whole body 18FDG PET/CT in our patients was 
significantly lower if not the lowest. We suggest adhering 
to recently published dose reducing strategies, use of ToF 
scanner with CT dose reducing option to achieve this 
lower if not the lowest effective dose. This would certainly 
reduce the risk of second primary malignancy in younger 
Maseeh uz Zaman et al
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patients with higher odds of cure from first primary cancer.
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